Program assessment, Product assessment, Competitive Landscape Analysis, Stakeholder Analysis, Scientific Due Diligence, Regulatory Strategy, Forecasting, Target Product Profile, Market Assessment, Development Plan, Investor Pitch


Platforms and Therapeutics


To provide Business Development advisory, Competitive Landscape Analysis, Scientific Due Diligence, and Market Assessment for a number of projects

“Novateur team was able to help us address a number of critical commercial and regulatory issues facing one of our start-up companies working in the cell therapy and oncology field. Novateur delivered actionable recommendations that allowed us to deliver a clear and complete business plan to potential investors. On a separate mandate we utilized Novateur’s business development experts to advise us on partnerships.”

Steven J. Klein, PhD, MBA
Vice-President, Business Development, IRICoR


Quebec-based non-for-profit organization engages Novateur experts for business development and scientific due diligence advisory support

Since 2017, IRICoR has engaged Novateur’s team of experts for a number of mandates. Those included Business Development advisory, Competitive Landscape Analysis, Scientific Due Diligence, and Market Assessment for a number of its projects. Novateur continues to support IRICoR on a number of projects, including those being spun-off into new companies. 

One of these projects has been the Tumor Specific Neo-antigen technology developed by Dr. Claude Perreault and Dr. Pierre Thibault, both principal investigators at IRICoR. 

Novateur was engaged to support business development of this technology in 2018 and assisted in out-licensing efforts. In 2021, together with top tiered Canadian and British VCs, Epitopea was founded in 2021 and and a seed round of $14M was raised in 2022. 


For more information about Epitopea visit: 

Claude Perreault and Pierre Thibault, founders of Epitopea, a company that offers hope for the treatment of cancer (Published on May 26, 2022)


Learn more about Epitopea


Learn more about IRICoR


Press Release (May 18, 2022): Novateur Ventures Participates in Founding and Financing of Epitopea, a New Cancer Therapeutics Company

"Novateur Ventures, a leading global life sciences advisory firm, announced it has participated in the $13.6M (£10.3M) seed investment raised by Epitopea, a cancer therapeutics company recently spun out of the Université de Montréal (UdeM) / IRIC in partnership with IRICoR. This investment will support the further development and application of Epitopea’s ground-breaking approaches to identify shared, aberrantly expressed tumor-specific antigens (TSA), that Epitopea has exclusively licensed from UdeM."

Novateur Newsletter

Subscribe to our newsletter for access to latest updates.

Resource Databases

Access Novateur news as well as FDA and Expert Databases.

Relevant Events

Check out conferences and events we are attending!